Changes in Gene Methylation Following Chemotherapy in Breast Cancer Cell Lines

ARI F., Napieralski R., Ulukaya E.

TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, cilt.38, sa.2, ss.154-162, 2013 (SCI-Expanded) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 38 Sayı: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.5505/tjb.2013.46320
  • Dergi Adı: TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
  • Sayfa Sayıları: ss.154-162
  • Anahtar Kelimeler: DNA methylation, breast cancer, apoptosis, decitabine, FEC, O-6-METHYLGUANINE DNA METHYLTRANSFERASE, PROMOTER HYPERMETHYLATION, PROTEIN-KINASE, CLINICAL-SIGNIFICANCE, LUMINESCENCE ASSAY, REPAIR GENES, SERUM DNA, EXPRESSION, TUMOR, DEMETHYLATION
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Objective: Epigenetic modulation of gene expression by DNA promoter methylation may contribute to acquired resistance to chemotherapy in cancer cells. Decitabine (5-aza-2'-deoxycytidine), a demethylating agent, may act synergistically with standard chemotherapy regimens to activate epigenetically silenced genes. In the present in vitro study, it was investigated the effect of gene methylation level after treatment with decitabine and combination of decitabine with anthracycline-based therapeutics (5-fluorouracil plus epirubicine plus cyclophosphamide; FEC) on breast cancer cells (MCF-7 and MDA-MB-231).